

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kathleen A. Elias

Application No.: 10/082,036

Filed: February 20, 2002

Title: METHOD OF CHARACTERIZING

POTENTIAL THERAPEUTICS BY

DETERMINING CELL-CELL

INTERACTIONS

TOP002D.

RECEIVED

TECH CENTER 1600/2900 Attorney Docket No.: CYTOP002D1

Examiner: Unassigned

Group: 1631

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail to: Commissioner for Patents, Washington DC 20231 op March 17, 2003.

Signed:

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Dear Sir:

The references listed in the attached PTO Form 1449, copies of which are attached, may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application.

37 CFR §§1.56 AND 1.97(b)

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. CYTOP002D1).

Respectfully submitted,


BEYER WEAVER & THOMAS, LLP

Lauren L. Stevens, Ph.D.

Lawn 2 s-

Registration No. 36,691

P.O. Box 778 Berkeley, CA 94704-0778



Information Disclosure Statement By Applicant

Atty Docket No. CYTOP002D1 Applicant: Kathleen A. Elias Application No.: 10/082,036 YCENT ZO

Filing Date February 20, 2002 1631

(Use Several Sheets if Necessary)

Patent Documents

			U.S. I atc	nt Documents			16-
Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub- class	Filing Opposite Date
THE STATE OF THE S		5,326,691	07/05/94	Hozier	Class	Class	Buile S
	В	5,355,215	10/11/94	Schroeder et al.			

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication			Sub-	Translation	
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
	C.	93/21511	28.10.93	PCT				
	D	94/11841	26.05.94	PCT				
	E.	96/09605	28.03.96	PCT				
	F-	97/43732	20.11.97	PCT				
	G.	99/05323	04.02.99	PCT		T	1	
	H	00/70528	23/11/00	PCT			1	

Other Documents

Examiner						
Initial	No.					
	I	Adams et al., "Cell patterning on glass and polymeric substrates" US Patent				
		Application No. 60/138,119, filed June 7, 1999				
	J	Kapur et al., "Design and Fabrication of Spatically Controlled Miniaturized				
1 1		Organ Systems from Stem Cells", US Patent Application No. 60/127,339,				
		filed April 1, 1999				
	K,	Hofland et al., "Role of Tumor – Derived Fibroblasts in the Growth of				
	}	Primary Cultures of Human Breast-Cancel Cells: Effects of Epidermal				
	}	Growth Factor and the Somatostatin Analogue Octreotide", 1995, Int. J.				
		Cancer: 60, 93-99.				
	L	Stearns et al., "Interleukin 10 (IL-10) inhibition of primary human prostate				
		cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of				
	}	metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)				
		2/MMP-9 Secretion", January 1999, Clinical Cancer Research, vol. 5 189-196				
	M .	. Takayama et al., "Patterning cells and their environments using multiple				
		laminar fluid flows in capillary networks", May 1999, Proc. Natl., Acad. Sci.				
		USA, vol. 96, pp. 5545-5548.				
Examiner		Date Considered				

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.